Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent Mother-to Child Transmission of HIV-1 o, Resource-Limited Settings: A Multicentre Randomized Phase 3 Clinical Trial.

Trial Profile

Safety and Efficacy of the Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations in Pregnant and Breastfeeding Women to Prevent Mother-to Child Transmission of HIV-1 o, Resource-Limited Settings: A Multicentre Randomized Phase 3 Clinical Trial.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2012

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Lamivudine/zidovudine; Lopinavir/ritonavir
  • Indications HIV infections; Pregnancy
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Feb 2012 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 17 Jun 2011 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
    • 15 Jul 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top